These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 21830840)

  • 1. Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.
    Stefansdottir G; De Bruin ML; Knol MJ; Grobbee DE; Leufkens HG
    Drug Saf; 2011 Sep; 34(9):783-92. PubMed ID: 21830840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rofecoxib for osteoarthritis.
    Garner SE; Fidan DD; Frankish R; Maxwell L
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD005115. PubMed ID: 15654705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
    Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012537. PubMed ID: 28770976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
    Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
    Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib for rheumatoid arthritis.
    Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
    Stiller CO; Hjemdahl P
    J Intern Med; 2022 Oct; 292(4):557-574. PubMed ID: 35585779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
    Prescrire Int; 2001 Apr; 10(52):46-9. PubMed ID: 11718158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.